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Viable Mycobacterium tuberculosisA B S T R A C T
There is an urgent need for a rapid and reliable test to detect actively multiplying Mycobac-
terium tuberculosis directly from clinical specimens for an early initiation of the appropriate
antituberculous treatment. This study was aimed at the optimization and application of
nested reverse transcriptase–PCR (nRT–PCR) targeting the messenger RNA of the icl2, hspx,
and rRNAP1 genes directly from sputum specimens, and their evaluation against the cul-
ture by the BACTEC MicroMGIT mycobacterial culture system. 203 Sputum samples from
clinically suspected tuberculosis patients and 30 control specimens (clinically proven viral
or bacterial infections other than tuberculosis) were included in this study. The mycobac-
terial culture was performed by the BACTEC MicroMGIT system following the manufac-
turer’s instructions. The primers for nRT–PCRs targeting icl2, hspx, and rRNAP1 genes
were indigenously designed using the Primer-BLAST software, and optimized for sensitivity
and specificity. The icl2, hspx, and rRNAP1 genes were able to pick up 63.9%, 67.2%, and
58.75%, respectively, of culture-negative sputum specimens collected from clinically sus-
pected tuberculosis patients. However, three (1.4%) were negative for nRT–PCR, butM. tuber-
culosis culture positive. All the 30 controls were negative for culture by the BACTEC
MicroMGIT method and all three nRT–PCR. The novel nRT–PCRs targeting icl2, hspx, and
rRNAP1 genes developed in this study are rapid and reliable diagnostic tools to detect viable
M. tuberculosis directly from sputum specimens. However, further study by including a lar-
ger number of sputum specimens needs to be carried out to ascertain the diagnostic utility
of the novel nRT–PCRs optimized in the study.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.r: 41, Old
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Mycobacterium tuberculosis, the causative agent of tuberculosis
(TB), infects approximately 2 billion people worldwide, and is
the leading cause of mortality due to this disease. The diagno-
sis of TB is difficult in situations where clinical diagnosis is
suggestive, but bacteriological proof is lacking. The detection
of acid-fast bacilli (AFB) by conventional microscopy is simple
and rapid, but lacks adequate sensitivity, whereas culture is
comparatively more sensitive and specific, but the result is
available after several weeks [1]. Hence, there is a need for
an alternative diagnostic method, which is specific, sensitive,
and rapid, particularly so when bacteriological proof of diag-
nosis is lacking. In recent years, the polymerase-chain-
reaction (PCR) test has been found to be useful for rapid diag-
nosis of TB directly from clinical specimens [1].
The gene of M. tuberculosis, icl2 (RV0467), encoding for isoc-
itrate lyase was previously demonstrated to play a pivotal role
in the intracellular metabolism of actively multiplying M.
tuberculosis. Isocitrate lyase is one of the key enzymes of the
glyoxylate metabolism shunt [2]. During the growth on C2
substrates, such as fatty acids or acetate, most microorgan-
isms employ the glyoxylate shunt as the main metabolic
route for the biosynthesis of cellular materials, and survive
inside the host macrophages. The hspx gene (Rv 2031c)
encodes the a-crystalline homologue protein. It is a 16-kDa
heat shock protein required for mycobacterial persistence
within the macrophage [2]. Many reports state that the hspx
gene is upregulated in macrophages during the initial stages
of TB. A recent report highlighted the high levels of hspxmes-
senger RNA (mRNA) in log-phase cultures ofM. tuberculosis [3].
Experimental evidence also indicated that the hspx gene level
is elevated during the growth of M. tuberculosis in cultured
macrophages [3]. The rRNAP1 gene (X58890.1) of M. tuberculo-
sis is a noncoding ribosomal promoter region, mainly
involved in the transcription of M. tuberculosis. The rrnA-P1,
one of the five rrn promoters in mycobacteria, has been
described as a novel target to detect M. tuberculosis [4]. The
present study is focused on targeting the mRNA of the icl2,
hspx, and rRNAP1 genes to detect the presence of actively
multiplying M. tuberculosis directly on sputum specimens
from clinically suspected TB patients for an early initiation
of the antituberculous treatment.Table 1 – Complementary DNA conversion protocol.
Reagents Volume (lL) IncubationMaterials and methods
The study was carried out at Larsen and Toubro Microbiology
Research Centre, Vision Research Foundation, Chennai, India.
The study (study code: 93-2007-P) was approved by the
Research Cell and Ethics Sub-Committee (Institutional Review
Board, Vision Research Foundation on March 21, 2008).dNTP mix 1 37 C for 1 h
RT buffer 1
Oligo-dt 1
Milli-Q 11.5
RT enzyme 0.5
RNA 5
Note: dNTP = deoxynucleotide triphosphate; dt = deoxythymine;
RT = reverse transcription.Sputum collection
A total of 203 sputum specimens from clinically suspected TB
patients attending the out patient department (OPD) at the
Institute of Thoracic Medicine, Chetput, Chennai, India, and
30 control sputum specimens (from clinically proven non-
TB patients) collected from March 2013 to July 2013 wereincluded in this study. The informed consent was obtained
from all the patients included in the study. The sputum spec-
imens were collected in new vials coated with sterile 0.1%
diethyl pyrocarbonate to prevent RNA degradation. The col-
lected sputum specimens were transported to the laboratory
within an hour of collection.
Processing of sputum specimens
Direct smear study
Ziehl–Neelsen staining was performed on all direct and con-
centrated smears of 203 sputum specimens to look for the
presence of AFB according to the Revised National Tuberculo-
sis Control Programme guidelines.
Culture for isolation of M. tuberculosis
The sputum samples were decontaminated using the modi-
fied Petroff’s method (n-acetyl-L-cysteine/sodium-hydroxide
method) following the instructions given in the BACTECman-
ual (Becton Dickinson diagnostics, New Jersey, United states),
and inoculated in MicroMGIT tubes. The inoculated tubes
were incubated at 37 C for 42 days, and readings were taken
every day.
RNA extraction and complementary DNA conversion
RNA extraction was carried out using the TRIzol method fol-
lowed by complementary DNA (cDNA) conversion (Table 1)
of the RNA using the Sensiscript reverse-transcription kit
(Qiagen, Valencia, California).
Performance of nested reverse transcriptase–PCRs targeting
the icl2, hspx, and rRNAP1 genes
After cDNA conversion by the Sensiscript reverse-
transcription kit (ABI Biosystems, Waltham, Massachusetts,
USA), the nested reverse transcriptase–PCRs (nRT–PCRs) tar-
geting the icl2, hspx, and rRNAP1 genes were performed. The
primer sets (both inner and outer sets of primers) targeting
the mRNA of the icl2, hspx, and rRNAP1 genes were designed
indigenously using the Primer-BLAST software from the
National Center for Biotechnology Information (NCBI). The
primers designed are given in Table 2. The primers were
checked by BLAST search and matching with the sequence
available in NCBI for specificity.
Table 2 – Details of primer sequence, thermal profile, and amplicon size used to standardize nested reverse transcriptase–
polymerase chain reactions.
Primer sequence (50–30) (indigenously
designed primers)
Nucleotide positions of
the primers within
the genes
Thermal profile No. of cycles Amplicon
size (bp)
icl2 gene (total length: 1287 base pairs)
First-round primer sets
ICLP1F:GAAGGCCATCTACCTGTCGG
ICLPIR:ACCGGTCTCCATCCAGATCA
255–861 94 C for 1 min
64 C for 1 min
72 C for 1 min
30 607
Second-round primer sets
ICLP5F:GCCTGAAGGCCATCTACCTG
ICLP5R:ATCACCACCGTGGGAACATC
251–677 94 C for 1 min
64 C for 1 min
72 C for 1 min
25 427
hspx gene (total length: 635 base pairs)
First-round primer sets
HSPP3F: CGGCTGGAAGACGAGATGAA
HSPP3R: CGCCACCGACACAGTAAGAA
145–400 94 C for 1 min
64 C for 1 min
72 C for 1 min
30 261
Second-round primer sets
HSPP1F: TTATGGTCCGCGATGGTCAG
HSPP1R: AATGCCCTTGTCGTAGGTGG
440–600 94 C for 1 min
64 C for 1 min
72 C for 1 min
25 161
rRNAP1 gene (total length: 478 base pairs)
First-round primer sets
RRNAP1F5: TCACGGAGAACGTGTTCGAG
RRNAP1R5: ACAACACGCTTGCTTGTTTCC
53–459 98 C for 10 s
60 C for 30 s
72 C for 1 min
35 407
Second-round primer sets
RRNAP1F4: CGTGGAGAACCTGGTGAGTC
RRNAP1R4: ACACGCTTGCTTGTTTCCG
291–456 98 C for 10 s
62 C for 30 s
72 C for 30 s
25 166
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icl2 and hspx genes
A 25-lL PCR reaction includes 22 lL of cocktail consisting of
200 lM of each deoxynucleotide triphosphate (deoxyadeno-
sine triphosphate, deoxythymidine triphosphate, deoxygua-
nosine triphosphate, and deoxycytidine triphosphate), 1 lM
of each primer set, and 10  buffers (10 mM Tris–HCl [pH
8.3], 50 mM KCl, 1.5 mM MgCl2), and 1 unit of Taq DNA poly-
merase was aliquoted into each vial. The negative control
was placed inside the PCR machine, and 3 lL of cDNA was
added into the respective labeled vials, and 3 lL of positive-
control cDNA (H37Rv) was pipetted into the vial labeled as
positive control. For the second round, 2.5 lL of the amplified
product was transferred to the second-round cocktail.
Cocktail preparation for nRT–PCR targeting the mRNA of the
rRNAP1 gene
A 25-lL PCR reaction, including 12.5 lL of Emerald GT Master
Mix (Takara Bio. inc., Shiga, Japan), 10 lL of GTwater, and 1 lM
of each primer set, was prepared. The negative control was
placed inside the PCR machine, and 1.5 lL of cDNAwas added
into the respective labeled vials, and 1 lL of positive-control
cDNA (H37Rv) was pipetted into the vial labeled as the posi-
tive control. For the second round, 2 lL of the amplified pro-
duct was transferred to the second-round cocktail (Table 2).
Determination of analytical sensitivity of nRT–PCRs targeting
the icl2, hspx, and rRNAP1 genes
The analytical sensitivity of the nRT–PCRs was performed by
serial tenfold dilutions of cDNA. Briefly, 10 Eppendorf(Hamburg, Germany) vials (0.5 mL) were taken and labeled
from 101 to 1010 dilution. Then, 45 lL of sterile milliQ water
(Merck Millipore, Ontario, Canada) was taken in each vial, and
5 lL of freshly extracted cDNA was added to the first vial. It
was mixed well, and 5 lL was transferred to the next vial.
Serial dilutions were performed until the last vial, and 5 lL
was discarded from the last dilutions followed by the perfor-
mance of nRT–PCRs for determining the sensitivity of the
primers.
Determination of specificity of nRT–PCRs targeting the icl2,
hspx, and rRNAP1 genes
The specificity of the primers was tested by amplifying the
cDNA from the following strains of mycobacterial species:
M. tuberculosis H37Rv and H37Ra, Mycobacterium bovis,
Mycobacterium intracellulare (American Type Culture Collection
[ATCC] 1403), Mycobacterium kansasii (ATCC 1201), Mycobac-
terium xenopi (ATCC 1432), Mycobacterium gordonae, Mycobac-
terium fortuitum (ATCC 1529), Mycobacterium chelonae (ATCC
1524), Mycobacterium abscessus (laboratory isolate), Mycobac-
terium smegmatis (ATCC 607), Mycobacterium phlei, Mycobac-
terium thermoresistibile, and Mycobacterium flavescens obtained
from the National Institute for Research in Tuberculosis
Research Centre, Indian Council of Medical research (ICMR)
unit, Chennai, India.
Detection of amplified products
After the nRT–PCR, 10 lL of the amplified product was sub-
jected to electrophoresis on 2% agarose gel incorporated with
0.5 lg/mL ethidium bromide for visualization by UV transillu-
minator (Vilber Lourmat, Marne La Vallee, France).
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Direct smear microscopy
Out of the 203 sputum specimens from clinically suspected
TB patients, 24 (11.8%) showed the presence of AFB by
Ziehl–Neelsen stain, and 179 were negative.
Mycobacterial culture by the MicroMGIT BACTEC method
Out of the 203 sputum samples collected from clinically sus-
pected TB patients, 48 (23.6%) sputum samples were culture
positive and 155 (76.3%) were culture negative. All M. tubercu-
losis isolates (48) were confirmed by PCR targeting the MPB64
gene, IS6110 [5] region, and TBc ID kit (BD Diagnostics, New
Jersey, USA). All the 30 control sputum specimens were nega-
tive for culture by the MicroMGIT BACTEC method.
Results of nRT–PCRs targeting the mRNA of the icl2 gene on
sputum samples
The designed primers were found specific and sensitive to
detect 64.2 pg for the detection of M. tuberculosis H37Rv cDNA
only. Out of the 203 sputum specimens from clinically sus-
pected TB patients, 111 (54.6%) were positive for nRT–PCR tar-
geting the icl2 gene. Among these, 24 (21.6%) were AFB smear
positive, 42 (37.8%) were culture positive, and 69 (62.1%) were
culture negative by the MicroMGIT BACTEC method, but six
culture-positive sputum specimens were negative for nRT–
PCR targeting the icl2 gene. All the 30 controls were negative
for nRT–PCR targeting the icl2 gene.
Results of nRT–PCRs targeting the mRNA of the hspx gene on
sputum specimens
The designed primers were found specific and sensitive to
detect 0.642 pg for the detection ofM. tuberculosisH37Rv cDNA
only. Out of the 203 sputum specimens, 107 (52.7%) were pos-
itive for nRT–PCR targeting the hspx gene. Among the 107 hspx
gene-positive clinical specimens, 24 (22.4%) were AFB smear
positive, 38 (35.5%) were culture positive, and 69 (64.4%) were
culture negative by the MicroMGIT BACTEC method, but 10
culture-positive sputum specimens were negative for nRT–
PCR targeting the hspx gene. All the 30 controls were negative
for nRT–PCR targeting the hspx gene.
Results of nRT–PCRs targeting the mRNA of the rRNAP1 gene
on sputum specimens
The designed primers were found specific and sensitive to
detect 0.642 pg for the detection ofM. tuberculosisH37Rv cDNA
only. Out of the 203 sputum specimens, 80 (39.1%) were
positive for nRT–PCR targeting the rRNAP1 gene. Among
these, 24 (30%) were AFB smear positive, 35 (43.75%) were
culture positive, and 45 (56.25%) were culture negative, but
13 culture-positive sputum specimens were negative for
nRT–PCR targeting the rRNAP1 gene. All the 30 controls were
negative for nRT–PCR targeting the rRNAP1 gene (Table 3).
The gel electrophoretograms of amplified products ofT tu
316 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 4 ( 2 0 1 5 ) 3 1 2 –3 1 7nRT–PCR targeting the icl2, hspx, and rRNAP1 genes are given
in Fig. 1.
Discussion
TB has been reported to be the major cause of death among
infectious diseases. The molecular markers of M. tuberculosis
viability are attractive, since results are rapid and there is a
potential for great analytical sensitivity [2]. Molecular diag-
nostic methods, like the reverse transcriptase–PCR, which
detects actively multiplying M. tuberculosis directly from spu-
tum specimens, help the clinicians to initiate proper antitu-
berculous treatment as early as possible, so that the rate of
spreading of TB can be controlled.
The main objective of this study was to standardize nRT–
PCRs targeting the mRNA of the icl2, hspx, and rRNAP1 genes
to efficiently detect actively multiplying M. tuberculosis
directly from clinical specimens, which paves the way for
the early initiation of appropriate anti-TB drugs.
Previous studies by Dietze et al. [6] have demonstrated that
DNA assays are not useful in monitoring response to therapy,
sinceM. tuberculosis DNA persists well beyond the time points
that cultures are positive. In another study, Li et al. [2] have
compared four different M. tuberculosis mRNA targets (85B,
hspx, icl2, and rRNAP1 genes) in the context of an early
bactericidal-activity study by comparing isoniazid with three
newer fluoroquinolones. They found that the icl2 mRNA was
determined to be the best marker based on high levels ofFig. 1 – Agarose-gel electrophoretograms showing second-roun
transcriptase–polymerase chain reaction targeting (A) icl2, (B) hs
ATCC = American Type Culture Collection.expression in sputum and strong correlation with colony-
forming-unit counts, both at baseline and during the 7 days
of isoniazid monotherapy. Mun˜oz-Elı´as and McKinney [7]
demonstrated that the icl2 gene coding for isocitrate lyase is
essential for M. tuberculosis growth and persistence in macro-
phages. In a study by Bwanga, Hoffner, Haile, and Joloba [8],
the transcription of the hspx gene isolated from an actively
replicating culture of M. tuberculosis was assessed, and they
found that the expression of hspx is enhanced in the actively
growing culture at 7 days and 10 days of culture of M.
tuberculosis.
In the present study, nRT–PCRs targeting the mRNA of the
icl2, hspx, and rRNAP1 genes were optimized using indige-
nously designed primers using the Primer-BLAST software
fromNCBI, and applied on 203 sputum specimens and 30 con-
trol specimens. The nRT–PCRs targeting the icl2 and hspx
genes have almost equal positivity with 54.1% and 52.7%,
respectively, to detect from clinically suspected TB patients
than the rRNAP1 gene with 39.1% positivity. In co-relation of
nRT–PCR results with that of the BACTEC culture, the icl2,
hspx, and rRNAP1 genes were able to pick up 63.9%, 67.2%,
and 58.75%more culture-negative sputum specimens, respec-
tively. None of the controls (30) were positive for both
mycobacterial culture by the BACTEC method and the nRT–
PCRs targeting the icl2, hspx, and rRNAP1 genes. Even though
in some cases, nRT–PCR was negative for any one of the opti-
mized genes, the remaining three genes were able to pick up
the viable M. tuberculosis from the clinical specimens. Thed complementary DNA amplification of nested reverse
px, and (C) rRNAP1 genes on sputum specimens.
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USA) was done for the three nRT–PCRs, and the sensitivity
was found to be 36.52% (confidence interval [CI] 27.74–
46.01%), 33.93% (CI 25.25–43.48%), and 41.67% (CI 31–52.94%)
for the icl2, hspx, and rRNAP1 genes, respectively. Whereas,
when all three nRT–PCRs were analyzed, the sensitivity was
increased to 94% with a CI of 82.78–98.62%. Therefore, target-
ing single gene will not be sufficient to detect viable M. tuber-
culosis from clinical specimens. So, all the three genes (icl2,
hspx, and rRNAP1 genes) must be targeted simultaneously to
improve the sensitivity to 100% to detect viable M. tuberculosis
from the clinical specimens. However, the nRT–PCR negativity
in culture-positive clinical specimens in this study was 1.4%.
This is one of the significant findings from our study. The 1.4%
false negativity in nRT–PCRs resulted in our study may be due
to the technical error encountered during collection, trans-
portation, and performance of the experiment. From the
results obtained in this study, we can also conclude that, if
the standardized nRT–PCRs were positive for two of the three
genes (icl2 and hspx, and rRNAP1 genes), it will provide 100%
sensitivity in the detection of actively multiplying M. tubercu-
losis directly from sputum specimens.
Conclusions
In conclusion, nRT–PCRs targeting all the three gene targets
optimized in this study need to be applied simultaneously
to increase the sensitivity to 100% to detect viable M. tubercu-
losis directly from clinical specimens, which helps in the ini-
tiation of an appropriate treatment to the patient. The
combinations of indigenously standardized nRT–PCRs are
definitely a useful contribution for the development of a rapid
molecular diagnostic test for the specific and rapid detection
of actively multiplying M. tuberculosis genome directly from
clinical specimens.
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